Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

Dr. Ikechukwu B. Moses, winner of the ESCMID Global 2025 Emerging Young Investigator Award, explores antimicrobial resistance through a One Health lens. His work spans zoonotic pathogen transmission, bacteriophage therapy, and AI-driven genomic research, aiming to reduce antibiotic reliance and translate lab-based innovations into scalable, real-world clinical and veterinary solutions.

Dr Dariusz Hareza reflects on ESCMID Global 2025, highlighting its international scope, informal collaboration, and key themes in antimicrobial resistance. He discusses impactful sessions on global surveillance, Kazakhstan’s primary care initiatives, and novel approaches like CRISPR and AI, all pointing toward an innovative and integrated future in infectious diseases.

The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...

Dr Simon Feys discusses his award-winning research on viral-associated pulmonary aspergillosis (VAPA) in critically ill patients, highlighting key insights into its pathophysiology, diagnostic challenges, and treatment gaps. His work combines clinical expertise with multi-omics analysis to improve understanding, detection, and management of this often-overlooked but potentially deadly fungal superinfection.

Dr Simon Feys discusses his journey into intensive care medicine, driven by the complexity and impact of treating critically ill patients. He highlights the central role of infections in ICU, the importance of broad medical knowledge, and how clinical experience and research together shape his approach to patient care and innovation.

Dr. Jon Salmanton-García discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.

Jon Salmanton-García discusses the challenges of diagnosing and treating invasive fungal infections in low- and middle-income countries, shares insights from studies in Peru and Honduras, and highlights key research and overlooked findings from ESCMID Global 2025.

For more than 40 years, Rebecca Denison has lived with HIV and advocated for women affected by the virus. A longtime activist and founder of WORLD, she has witnessed the epidemic’s evolution. In this interview, she reflects on scientific progress, ongoing challenges, and why the fight against HIV is far from over.